Biologics targeting CD4+T cell-related inflammatory cytokines can effectively inhibit immune inflammation in IBD, bringing about a breakthrough revolution in clinical practice (D’Haens and van Deventer, 2021). Here, CD4 is linked to inflammatory bowel disease.